BMY Bristol-Myers Squibb Company
Company Analysis
Latest News
Bristol Myers Squibb Wins EU Approval for Opdivo, First Lymphoma Immunotherapy Combo
The European Commission approved Bristol Myers Squibb’s Opdivo in combination with AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine). This regimen...
Bristol Myers Squibb cuts myeloma progression risk 52% with mezigdomide
Bristol Myers Squibb reported Phase 3 SUCCESSOR-2 trial results for its multiple myeloma drug, mezigdomide. The company presented these findings at the 2026...
Bristol-Myers Squibb maintains Buy rating, citing milvexian trial potential
UBS reaffirmed its Buy rating for Bristol-Myers Squibb. The investment bank set a price target of $70.00 for the stock. Analysts identify milvexian, a Factor...
Bristol Myers Squibb Partners with Anthropic to Deploy Claude AI Across Global Operations
Bristol Myers Squibb has partnered with Anthropic to deploy Claude as an enterprise-wide AI platform, aiming to accelerate drug discovery and operational...
Bristol-Myers Squibb invests $1B in Houston plant, targeting US supply chain
Bristol-Myers Squibb will build a US$1 billion pharmaceutical manufacturing facility in Houston. The project will create nearly 500 jobs. This expansion...
Bristol Myers Squibb Loses Supreme Court Challenge to Medicare Price Negotiations
The U.S. Supreme Court rejected a legal challenge from Bristol Myers Squibb against the Medicare drug price negotiation program on May 18, 2026. This ruling...
Bristol Myers Squibb Inks $15.2 Billion Hengrui Deal for 13 Drug Programs
Bristol Myers Squibb (BMS) signed a strategic licensing agreement with Chinese biotech firm Hengrui Pharma worth up to $15.2 billion. The collaboration...
Bristol Myers Squibb's first quarter 2026 revenue grew 3% driven by a 12% increase in its Growth Portfolio.
Bristol Myers Squibb reported first quarter 2026 revenue of $11.5 billion, an increase of 3% year-over-year, while non-GAAP EPS declined 12% to $1.58. The...
Bristol-Myers Squibb Company Q1 2026 Earnings Preview: What Analysts Expect on April 30, 2026
Bristol-Myers Squibb is expected to post Q1 2026 revenue of $10.92 billion and earnings of $1.44 per share, with the current stock price of $58.71 trailing the...